-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V9cqM8wkL6Ddw9cam7cpMTYEIHQ5O7+0XfkqgdkfxX/0+/4XLp3V8HQWcu80Hjhb JWGLSVvdBaK9cRB3XL3Exw== 0000950135-99-004177.txt : 19990823 0000950135-99-004177.hdr.sgml : 19990823 ACCESSION NUMBER: 0000950135-99-004177 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALKERMES INC CENTRAL INDEX KEY: 0000874663 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232472830 STATE OF INCORPORATION: PA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 424B3 SEC ACT: SEC FILE NUMBER: 333-75645 FILM NUMBER: 99697134 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139-4136 BUSINESS PHONE: 6174940171 424B3 1 ALKERMES, INC. 1 Prospectus Supplement No. 2 to Prospectus dated May 12, 1999 Filed Pursuant to Rule 424B(3) File No. 333-75645 ALKERMES, INC. 3,680,508 SHARES OF COMMON STOCK This Prospectus Supplement supplements information contained in that certain Prospectus of Alkermes, Inc. (the "Company") dated May 12, 1999 (the "Prospectus") relating to the potential resale from time to time of Common Stock, par value $.01 per share (the "Common Stock") issued upon consummation of the merger between the Company's subsidiary and Advanced Inhalation Research, Inc. This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto. Capitalized terms used herein but not defined have the meanings assigned to such terms in the Prospectus. The following table supplements the information set forth in the Prospectus under the caption "Selling Shareholders" with respect to the Selling Shareholders and the respective number of shares of Common Stock that may be sold by the Selling Shareholders pursuant to this Prospectus, as amended or supplemented:
NUMBER OF SHARES OF COMMON STOCK BENEFICIALLY AS OF AUGUST 18, 1999 OWNED AND PERCENTAGE OF SHARES THAT ARE THAT MAY BE OUTSTANDING NOT SUBJECT TO SOLD SUBJECT COMMON STOCK AS OF NAME RESTRICTION TO VESTING AUGUST 18, 1999(1) ---- --------------------- ------------ ------------------ DAVID A. EDWARDS(2) 0 591,556 2.34% ODEON INVESTMENTS, L.P.(2) 167,000 167,000 * GERMAIN CHARITABLE TRUST(2) 167,000 167,000 *
- --------------- * Less than 1% of the outstanding Common Stock. (1) On August 18,1999, there were 25,250,637 shares of Common Stock outstanding. (2) David A. Edwards is the Chief Scientific Officer of Advanced Inhalation Research, Inc., a wholly owned subsidiary of the Company. Dr Edwards is the sole limited partner and owner of the general partner of Odeon Investments, L.P. Dr. Edwards is a beneficiary, and not the trustee, of the Germain Charitable Trust. THE DATE OF THIS PROSPECTUS SUPPLEMENT IS AUGUST 20, 1999 -----END PRIVACY-ENHANCED MESSAGE-----